scutellarin has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ji, LL; Jia, WY; Lu, B; Mei, XY; Wang, MN; Zhang, JN; Zhang, TY | 1 |
| Ji, L; Jia, W; Lu, B; Mei, X; Ouyang, H; Zhang, H; Zhang, J | 1 |
2 other study(ies) available for scutellarin and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Scutellarin suppresses triple-negative breast cancer metastasis by inhibiting TNFα-induced vascular endothelial barrier breakdown.
Topics: Apigenin; Cell Line, Tumor; Glucuronates; Human Umbilical Vein Endothelial Cells; Humans; Protein Kinases; Receptors, Tumor Necrosis Factor, Type II; Triple Negative Breast Neoplasms; Tumor Necrosis Factor-alpha | 2022 |
Scutellarin suppresses the metastasis of triple-negative breast cancer via targeting TNFα/TNFR2-RUNX1-triggered G-CSF expression in endothelial cells.
Topics: Animals; Cell Line, Tumor; Core Binding Factor Alpha 2 Subunit; Granulocyte Colony-Stimulating Factor; Human Umbilical Vein Endothelial Cells; Humans; Mice; Receptors, Tumor Necrosis Factor, Type II; Triple Negative Breast Neoplasms; Tumor Necrosis Factor-alpha | 2023 |